Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Recommendation of "Moderate Buy" by Brokerages
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) have earned a consensus rating of "Moderate Buy" from the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $59.22.
据MarketBeat Ratings报道,箭头制药公司(纳斯达克代码:ARWR-GET Rating)的股票已被目前涵盖该股票的11家研究公司的共识评级为“适度买入”。三位研究分析师对该股的评级为持有建议,六位分析师对该公司发出了买入建议。在过去一年发布该股报告的分析师中,平均一年目标价为59.22美元。
Several research firms recently commented on ARWR. SVB Leerink cut their price target on Arrowhead Pharmaceuticals from $33.00 to $31.00 and set a "market perform" rating on the stock in a research note on Tuesday, November 29th. Chardan Capital cut their price target on Arrowhead Pharmaceuticals from $82.00 to $60.00 in a research note on Tuesday, January 10th. Piper Sandler cut their price target on Arrowhead Pharmaceuticals from $64.00 to $55.00 in a research note on Monday, January 9th. The Goldman Sachs Group reiterated a "buy" rating and issued a $66.00 price target (up previously from $65.00) on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 30th. Finally, Jefferies Financial Group cut their price target on Arrowhead Pharmaceuticals from $92.00 to $75.00 and set a "buy" rating on the stock in a research note on Tuesday, November 29th.
几家研究公司最近对ARWR发表了评论。SVB Leerink在11月29日(星期二)的一份研究报告中将箭头制药的目标价从33.00美元下调至31.00美元,并对该股设定了“市场表现”评级。Chardan Capital在1月10日星期二的一份研究报告中将箭头制药的目标价从82.00美元下调至60.00美元。派珀·桑德勒在1月9日周一的一份研究报告中将他们对箭头制药的目标价从64.00美元下调至55.00美元。11月30日,周三,高盛在一份研究报告中重申了买入评级,并对箭头制药的股票发布了66.00美元的目标价(之前的目标价为65.00美元)。最后,杰富瑞金融集团在11月29日星期二的一份研究报告中,将箭头制药的目标价从92.00美元下调至75.00美元,并对该股设定了“买入”评级。
Insider Buying and Selling at Arrowhead Pharmaceuticals
箭头制药公司的内幕买卖
In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,200 shares of the company's stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $30.00, for a total transaction of $96,000.00. Following the sale, the director now owns 28,950 shares in the company, valued at $868,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director William D. Waddill sold 3,200 shares of the stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $30.00, for a total transaction of $96,000.00. Following the sale, the director now directly owns 28,950 shares in the company, valued at approximately $868,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Martin Javier San sold 19,500 shares of the stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $29.99, for a total value of $584,805.00. Following the sale, the insider now owns 91,500 shares in the company, valued at $2,744,085. The disclosure for this sale can be found here. Insiders have sold 109,966 shares of company stock worth $4,050,435 over the last quarter. 3.20% of the stock is owned by corporate insiders.
在其他箭头制药公司的消息中,董事威廉·D·沃迪尔在1月9日星期一的一笔交易中出售了3,200股该公司股票。该股以30.00美元的平均价格出售,总成交金额为9.6万美元。交易完成后,董事现在拥有该公司28,950股股份,价值868,500美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在这个环节。其他消息方面,董事威廉·D·沃迪尔在1月9日(星期一)的一笔交易中出售了3200股该公司股票。该股以30.00美元的平均价格出售,总成交金额为9.6万美元。交易完成后,董事现在直接持有该公司28,950股股份,价值约868,500美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可以通过美国证券交易委员会网站。此外,内部人士马丁·哈维尔·桑在11月21日星期一的一笔交易中出售了19,500股该股。这只股票的平均售价为29.99美元,总价值为584,805.00美元。出售后,这位内部人士现在拥有该公司91,500股,价值2,744,085美元。关于这次销售的披露可以找到这里。在上个季度,内部人士已经出售了109,966股公司股票,价值4,050,435美元。3.20%的股份由企业内部人士持有。
Institutional Trading of Arrowhead Pharmaceuticals
箭头药品的机构性交易
Arrowhead Pharmaceuticals Price Performance
箭头药品价格表现
Shares of NASDAQ ARWR opened at $36.82 on Tuesday. Arrowhead Pharmaceuticals has a 1-year low of $26.81 and a 1-year high of $58.96. The business has a 50-day moving average of $33.74 and a 200-day moving average of $36.71. The company has a market capitalization of $3.90 billion, a price-to-earnings ratio of -21.92 and a beta of 1.26.
周二,纳斯达克arwr的股价开盘报36.82美元。箭头制药的一年低点为26.81美元,一年高位为58.96美元。该业务的50日移动均线切入位在33.74美元,200日移动均线切入位在36.71美元。该公司市值为39亿美元,市盈率为-21.92倍,贝塔系数为1.26。
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last issued its earnings results on Monday, November 28th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.24). Arrowhead Pharmaceuticals had a negative return on equity of 40.23% and a negative net margin of 71.01%. The company had revenue of $31.58 million during the quarter, compared to analysts' expectations of $107.60 million. Research analysts expect that Arrowhead Pharmaceuticals will post -0.59 EPS for the current fiscal year.
箭头制药(纳斯达克:ARWR-GET评级)最近一次发布财报是在11月28日(星期一)。这家生物技术公司公布了本季度每股收益(0.81美元),低于普遍预期的(0.57美元)和(0.24美元)。箭头制药的净资产收益率为负40.23%,净利润率为负71.01%。该公司本季度营收为3158万美元,高于分析师预期的1.076亿美元。研究分析师预计,箭头制药公司本财年的每股收益将为0.59美元。
About Arrowhead Pharmaceuticals
关于箭头制药公司
(Get Rating)
(获取评级)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis.
箭头制药公司在美国开发治疗顽固性疾病的药物。该公司正在筹备中的产品包括用于治疗与α-1抗胰蛋白酶缺乏相关的肝病的候选RNA干扰(RNAi)药物ARO-AAT,处于第二阶段临床试验的ARO-APOC3,处于2b期和治疗高甘油三酯血症的第三阶段临床试验的ARO-APOC3,治疗血脂异常的2b期临床试验的ARO-ANG3,用于治疗肝病的第1/2期临床试验的ARO-HSD,用于治疗血脂异常囊性纤维化的临床前阶段的ARO-ENaC2;ARO-C3,用于减少补体成分3的产生,处于第1/2a期临床试验;ARO-DUX4,用于治疗面部肩臂肌营养不良,处于临床前阶段;ARO-XDH,用于治疗不受控制的痛风;ARO-COV,处于治疗新冠肺炎的临床前阶段;ARO-RAGE,用于治疗粘液阻塞性或炎症性肺部疾病,处于1/2a期临床试验;以及ARO-MMP7,处于1/2期临床试验,用于治疗特发性肺纤维化。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Pinterest is the Social Commerce Platform to Watch in 2023
- 4 High-Yield Dividend Kings For 2023
- Will 2023 be a Good Year for Goodyear Tire Stock?
- 免费获取StockNews.com关于箭头制药的研究报告(ARWR)
- 为什么华纳兄弟探索成为标准普尔最热门的股票
- 沃尔格林靴子联盟的收益低于预期对投资者有利吗?
- Pinterest是2023年值得关注的社交商务平台
- 2023年4大高收益股利之王
- 2023年对固特异轮胎库存来说会是一个好年份吗?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《箭头药业日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对箭头制药和相关公司的最新新闻和分析师评级的每日简要摘要。